SyntheMed Nominated for Frost & Sullivan Award

antiadhesionbarrier-smallSyntheMed, a biomaterials company engaged in the development and commercialization of anti-adhesion products, has been nominated for the prestigious Frost & Sullivan Health Innovation Award in pediatrics. The Iselin, NJ-based company was recognized for its REPEL-CV Anti-Adhesion Barrier, a thin film designed to be placed over the heart at the conclusion of open-heart surgery to reduce the formation of post-surgical adhesions. REPEL-CV is approved by the U.S. Food and Drug Administration for use in pediatric cardiac surgery. The Frost & Sullivan Health Innovation Award is presented annually to a medical device company demonstrating innovation in new product development.

Related post: SyntheMed’s REPEL-CV Approved by Australian Regulators

  1. » SyntheMed Receives Endorsement, New Patent | OneMedPlace » Archive

    on August 7, 2009

    […] June, REPEL-CV was nominated for the prestigious Frost & Sullivan Health Innovation Award in pediatrics. The award is […]


Add Your Comments